BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 30532951)

  • 21. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model.
    Madhankumar AB; Slagle-Webb B; Wang X; Yang QX; Antonetti DA; Miller PA; Sheehan JM; Connor JR
    Mol Cancer Ther; 2009 Mar; 8(3):648-54. PubMed ID: 19276162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in the Use of Lipid-Based Nanoparticles Against Glioblastoma Multiforme.
    Ortega-Berlanga B; Gonzalez C; Navarro-Tovar G
    Arch Immunol Ther Exp (Warsz); 2021 Mar; 69(1):8. PubMed ID: 33772646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
    Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
    BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
    Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
    Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma.
    Meng L; Wang C; Lu Y; Sheng G; Yang L; Wu Z; Xu H; Han C; Lu Y; Han F
    ACS Appl Mater Interfaces; 2021 Mar; 13(10):11657-11671. PubMed ID: 33684289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of doxorubicin in glioblastoma multiforme following ultrasound-Induced blood-brain barrier disruption as determined by microdialysis.
    Lin YL; Wu MT; Yang FY
    J Pharm Biomed Anal; 2018 Feb; 149():482-487. PubMed ID: 29175555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of blood-brain barrier-stealth nanocomposites for in situ glioblastoma theranostics applications.
    Su CH; Tsai CY; Tomanek B; Chen WY; Cheng FY
    Nanoscale; 2016 Apr; 8(15):7866-70. PubMed ID: 27035391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
    Gaillard PJ; Appeldoorn CC; Dorland R; van Kregten J; Manca F; Vugts DJ; Windhorst B; van Dongen GA; de Vries HE; Maussang D; van Tellingen O
    PLoS One; 2014; 9(1):e82331. PubMed ID: 24416140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-Borneol induces transient opening of the blood-brain barrier and enhances the therapeutic effect of cisplatin.
    Yin Y; Cao L; Ge H; Duanmu W; Tan L; Yuan J; Tunan C; Li F; Hu R; Gao F; Feng H
    Neuroreport; 2017 Jun; 28(9):506-513. PubMed ID: 28471848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
    Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
    Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
    Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
    Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma.
    Zhang Y; Zhang L; Hu Y; Jiang K; Li Z; Lin YZ; Wei G; Lu W
    J Control Release; 2018 Nov; 289():102-113. PubMed ID: 30243823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
    Brighi C; Reid L; Genovesi LA; Kojic M; Millar A; Bruce Z; White AL; Day BW; Rose S; Whittaker AK; Puttick S
    Theranostics; 2020; 10(14):6361-6371. PubMed ID: 32483457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases.
    Guo Q; Zhu Q; Miao T; Tao J; Ju X; Sun Z; Li H; Xu G; Chen H; Han L
    J Control Release; 2019 Jun; 303():117-129. PubMed ID: 31026546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.
    Lin YL; Chang KF; Huang XF; Hung CL; Chen SC; Chao WR; Liao KW; Tsai NM
    Int J Nanomedicine; 2015; 10():6009-20. PubMed ID: 26451107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy of glioblastoma by targeted liposomal platinum compounds with focused ultrasound.
    Yang FY; Horng SC
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():6289-92. PubMed ID: 24111178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes.
    Gao JQ; Lv Q; Li LM; Tang XJ; Li FZ; Hu YL; Han M
    Biomaterials; 2013 Jul; 34(22):5628-39. PubMed ID: 23628475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.